Journey Medical Corp Announces New Journey with the Experts Video Featuring Marisa Garshick, MD — Journey Medical Corporation
Dr. Garshick discusses hyperhidrosis, a dermatologic condition with an estimated prevalence of 15.3 million people in the United States
SCOTTSDALE, Ariz. – April 16, 2021 – PRLog — Journey Medical Corporation (Journey Medical) today released a new Journey with the Experts video featuring Marisa Garshick, MD, a board-certified dermatologist with Medical Dermatology and Cosmetic Surgery in New York, New York. Dr. Garshick sits down with Journey Medical to discuss hyperhidrosis, including what it is, why it occurs and how those affected can seek treatment from their local dermatology practice.
Hyperhidrosis is abnormally excessive sweating involving the extremities, underarms, and face, usually unrelated to body temperature or exercise. To view the Journey with the Experts video featuring Dr. Garshick, please visit https://vimeo.com/
About Journey with the Experts
Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.
About Journey Medical Corporation
Journey Medical is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets seven products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO)
About Marisa Garshick, MD
Dr. Garshick is a leading board-certified dermatologist serving patients throughout Manhattan, New York at MDCS Dermatology:
She completed her undergraduate education at Emory University and attended medical school at Tufts University School of Medicine, where she graduated with Research Honors and Alpha Omega Alpha. As a medical student, Dr. Garshick was awarded the prestigious Doris Duke Clinical Research Fellowship at Harvard Medical School, during which she performed dermatology clinical trials and research at Massachusetts General Hospital. She was also awarded the American Medical Women’s Association Glasgow-Rubin Academic Achievement Award for graduating at the top of her class and the William Dameshek Award for Research Excellence.
Dr. Garshick’s post-graduate training in dermatology began with an internship at Memorial Sloan Kettering Cancer Center. She completed her dermatology residency at Cornell’s New York-Presbyterian Hospital, where she served as Chief Resident in Dermatology. Dr. Garshick has numerous publications in scientific journals and book chapters, including a chapter on the treatment of acne, and has presented at several national meetings. For additional information about Dr. Garshick, please visit https://www.mdcsnyc.com/
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually, a partner company individually, or Fortress together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships;
